Twenty years of global surveillance of antituberculosis-drug resistance

New England Journal of Medicine

Volumn 375, Issue 11, 2016, Pages 1081-1089

  Zignol, Matteo ^a   Dean, Anna S ^a   Falzon, Dennis ^a   Van Gemert, Wayne ^a   Wright, Abigail ^a   Van Deun, Armand ^b   Portaels, Françoise ^b   Laszlo, Adalbert ^c   Espinal, Marcos A ^e   Pablos Méndez, Ariel ^a,e   Bloom, Amy ^e   Aziz, Mohamed A ^d   Weyer, Karin ^a   Jaramillo, Ernesto ^a   Nunn, Paul ^a   Floyd, Katherine ^a   Raviglione, Mario C ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c LAB CENTRE FOR DISEASE CONTROL   (Canada)

^d PAN AMERICAN HEALTH ORGANIZATION   (United States)

^e UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BEDAQUILINE; CAPREOMYCIN; DELAMANID; GATIFLOXACIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; AUSTRIA; BELARUS; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; ESTONIA; FEASIBILITY STUDY; FINLAND; HEALTH CARE PERSONNEL; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAZAKHSTAN; KYRGYZSTAN; LATVIA; LITHUANIA; LUNG TUBERCULOSIS; MOLDOVA; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; RUSSIAN FEDERATION; STANDARDIZATION; SWEDEN; TREND STUDY; UKRAINE; UNITED KINGDOM; UZBEKISTAN; DRUG EFFECTS; HEALTH; HISTORY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; GLOBAL HEALTH; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84988353653     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsr1512438     Document Type: Article

References (49)

1. Resolution WHA67/25: antimicrobial resistance. Presented at the 67th World Health Assembly, Geneva, May 24, 2014 (Resolutions and Decisions; Annexes [WHASS1/2014WHA67/2014/REC/25]). Geneva: World Health Organization, 2014.
2. Crofton J, Mitchison DA. Streptomycin resistance in pulmo-nary tuberculosis. Br Med J 1948; 2: 1009-15.
3. Cohn ML, Middlebrook G, Russell WF Jr. Combined drug treatment of tuberculosis. I. Prevention of emergence of mutant populations of tubercle bacilli resistant to both streptomycin and isoniazid in vitro. J Clin Invest 1959; 38: 1349-55.
4. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tu-berculosis. Am Rev Respir Dis 1986; 133: 423-30.
5. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons-Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep 1991; 40: 585-91.
6. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cau-then GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-6.
7. Monno L, Angarano G, Carbonara S, et al. Emergence of drug-resistant Mycobacterium tuberculosis in HIV-infected pa-tients. Lancet 1991;337:852.
8. Moro ML, Gori A, Errante I, et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. AIDS 1998; 12: 1095-102.
9. Antimicrobial resistance: global report on surveillance 2014. Geneva: World Health Organization, 2014.
10. Guidelines for surveillance of drug resistance in tuberculosis: WHO/TB/94.178. Geneva: World Health Organization, 1994.
11. Guidelines for surveillance of drug resistance in tuberculosis: WHO/TB/96.216. Geneva: World Health Organization, 1997.
12. WHO treatment guidelines for drug-resistant tuberculosis: WHO/HTM/TB/2016.04: 2016 update. Geneva: World Health Or-ganization, 2016.
13. Guidelines for surveillance of drug resistance in tuberculosis. 4th ed.: WHO/TB/2009.422. Geneva: World Health Organi-zat ion, 2009.
14. Guidelines for surveillance of drug resistance in tuberculosis. 5th ed.: WHO/HTM/TB.13.2015. Geneva: World Health Or-ganization, 2015.
15. Laszlo A, Rahman M, Raviglione M, Bustreo F. Quality assurance programme for drug susceptibility testing of Mycobac-terium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing. Int J Tuberc Lung Dis 1997;1:231-8.
16. Laszlo A, Rahman M, Espinal M, Raviglione M. Quality assurance programme for drug susceptibility testing of Mycobac-terium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. Int J Tuberc Lung Dis 2002; 6: 748-56.
17. Van Deun A, Wright A, Zignol M, Weyer K, Rieder HL. Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis 2011;15:116-24.
18. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55: 301-5.
19. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80.
20. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance: WHO/TB/97.229. Geneva: World Health Organiza-t ion, 1997.
21. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Report 2: Prevalence and trends: WHO/CDS/TB/2000.278. Geneva: World Health Organization, 2000.
22. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Third global report: WHO/HTM/TB/2004.343. Geneva: World Health Organization, 2004.
23. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Fourth global report: WHO/HTM/TB/2008.394. Geneva: World Health Organization, 2008.
24. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response: WHO/HTM/TB/2010.3. Geneva: World Health Organization, 2010.
25. Pablos-Méndez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998;338:1641-9.
26. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-303.
27. Aziz MA, Wright A, Laszlo A, et al. Epidemiology of anti-tuberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006;368:2142-54.
28. Wright A, Zignol M, Van Deun A, et al. Epidemiology of anti-tuberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373:1861-73.
29. Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111-119D.
30. Zignol M, Sismanidis C, Falzon D, Glaziou P, Dara M, Floyd K. Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J 2013; 42: 701-7.
31. Dean AS, Zignol M, Falzon D, Getahun H, Floyd K. HIV and multidrug-resistant tuberculosis: overlapping epidemics. Eur Respir J 2014;44:251-4.
32. Cohen T, Jenkins HE, Lu C, McLaughlin M, Floyd K, Zignol M. On the spread and control of MDR-TB epidemics: an examination of trends in anti-tuberculosis drug resistance surveillance data. Drug Resist Updat 2014; 17: 105-23.
33. Global tuberculosis report 2015: WHO/HTM/TB/2015.22. Geneva: World Health Organization, 2015.
34. South African tuberculosis drug resistance survey 2012-2014. Sandringham, South Africa: National Institute for Communicable Diseases, 2016 (http://www.nicd.ac.za).
35. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009; 7: 81-7.
36. European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2016. Stockholm: European Centre for Disease Prevention and Control, 2016.
37. Jenkins HE, Plesca V, Ciobanu A, et al. Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J 2013; 42: 1291-301.
38. Mesfin YM, Hailemariam D, Biadgilign S, Kibret KT. Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis. PLoS One 2014; 9(1): e82235.
39. Falzon D, Jaramillo E, Wares F, Zignol M, Floyd K, Ravi-glione MC. Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis 2013;13:690-7.
40. Resolution WHA62/15: prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Presented at the 62nd World Health Assembly, Geneva, May 18-22, 2009 (Resolutions and Decisions; Annexes [WHA62/2009/REC/1]). Geneva: World Health Organization, 2009.
41. Uplekar M, Juvekar S, Morankar S, Rangan S, Nunn P. Tuberculosis patients and practitioners in private clinics in India. Int J Tuberc Lung Dis 1998; 2: 324-9.
42. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013; 42: 252-71.
43. Farhat MR, Shapiro BJ, Kieser KJ, et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet 2013; 45: 1183-9.
44. Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015;385:1738-47.
45. Zignol M, Dean AS, Alikhanova N, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazin-amide and fluoroquinolones: results from a multicountry sur-veillance project. Lancet Infect Dis 2016 July 7 (Epub ahead of print).
46. Cohen T, Hedt BL, Pagano M. Estimating the magnitude and direction of bias in tuberculosis drug resistance surveys conducted only in the public sector: a simulation study. BMC Public Health 2010;10:355.
47. Gupta R, Cegielski JP, Espinal MA, et al. Increasing trans-parency in partnerships for health-introducing the Green Light Committee. Trop Med Int Health 2002; 7: 970-6.
48. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002;295:2042-6.
49. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multi-drug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380: 1406-17.